US-headed biobased specialty chemicals company DMC Biotechnologies Inc. (DMC) has announced that it has entered into a multi-year collaboration agreement with Japan-headed global plastics and life sciences major Toyobo Co., Ltd. (Toyobo) to develop a more sustainable, fermentation-produced, high-volume chemical intermediate for use in a wide range of essential materials.
According to a statement, this partnership brings together DMC’s expertise in precision fermentation with Toyobo’s extensive chemical and biotechnology process knowledge, along with their broad access to global markets.
Toyobo is dedicated to driving innovations in sustainable materials and production. By integrating Toyobo’s chemical synthesis and biotechnology expertise with DMC’s advanced biotechnology platform, we aspire to create new opportunities for sustainable chemical products that meet global market demands, said Iizuka Norio, Executive Officer, Sustainability and Corporate Planning Division at Toyobo.
Leverage complementary capabilities
Through this agreement, the two companies will leverage their complementary capabilities to accelerate the development and commercialization of bio-based and affordable chemical products.
DMC will utilize its proprietary “Dynamic Metabolic Control” technology and metabolic engineering expertise to enable cost-advantaged, efficient, scalable, and robust fermentation processes, while Toyobo will leverage its extensive expertise in both chemical synthesis and biotechnology, along with its deep industry knowledge, to bring these innovative products to market.
We are excited to partner with Toyobo, a company with a long history of leadership in chemical innovation. This collaboration reflects our shared commitment to delivering sustainable, cost-effective solutions to the chemical industry. It also highlights how established industry leaders and innovative technology companies can come together to meet the moment, advancing more sustainable and secure supply chains for essential chemical products, said Jim Flatt, CEO of DMC Biotechnologies.
